Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Thalidomide Combined With Low-dose Hormones for Severe COVID-19 Pneumonia
NCT04273581Phase 2Unknown
- Sponsor
- The First Affiliated Hospital of Wenzhou Medical University
- Start
- Feb 2020
- Primary completion
- Apr 2020
- Modality
- Small Molecules
01
Overview
Phase 2, randomised, double-blind trial of thalidomide in coronavirus disease 2019 (COVID-19) (2 arms), sponsored by The First Affiliated Hospital of Wenzhou Medical University. Primary endpoint: Time to Clinical Improvement up to 28 days. Status: unknown.
02
Drugs
thalidomide
03
Conditions
coronavirus disease 2019 (COVID-19)
Beyond the preview
Go deeper on NCT04273581.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04273581.